Pacira BioSciences (PCRX) investor relations material

Strategic initiatives and growth outlook

• Rolled out the 5x30 strategy targeting 3 million patients by 2030, double-digit top-line growth, five-point margin expansion, five pipeline products, and five partnerships.

• Achieved a volume-limited settlement with Fresenius, providing IP visibility for EXPAREL through 2039 and supporting the patent estate.

• Signed key agreements with Johnson & Johnson MedTech to expand ZILRETTA's reach and with LG Chem for Asia Pacific coverage of EXPAREL and ZILRETTA.

• Focused on expanding payer coverage, especially outside bundled payments, with commercial payers now reimbursing up to ASP +29%.

• Ex-U.S. partnerships expected to generate significant revenues, with a focus on private pay in Asia and further expansion into Europe, Latin America, and Japan.

Product performance and reimbursement trends

• EXPAREL saw volume growth above 6% in the last year, up from 3% the previous year, driven by NOPAIN Act implementation and new GPO contracts.

• NOPAIN Act enabled separate reimbursement for Medicare outpatient settings, with commercial payers increasingly following suit.

• Volume and revenue growth expected to converge in the second half of the year as the last GPO contract laps.

• Dedicated sales forces established for each product, with EXPAREL prioritized for focused growth.

• Revenue guidance for 2026 projects 3%-6% total growth, with EXPAREL expected to grow 4%-8%.

Market adoption and clinical impact

• High clinician awareness of NOPAIN, with about half of surveyed pharmacy directors, anesthesiologists, and surgeons already adapting patient management.

• Data indicate NOPAIN is reducing opioid utilization and improving patient outcomes, supporting the case for its continuation.

• Commercial payer access and reimbursement are broadening, further supporting product adoption.

• Partnerships with leading companies are expected to drive adoption and revenue in new markets.